## **Core Concept**
Lenalidomide is an immunomodulatory drug used primarily in the treatment of multiple myeloma and certain types of lymphoma. It works by enhancing T-cell and natural killer cell-mediated immunity and has anti-angiogenic effects. However, one of its significant side effects is an increased risk of thromboembolic events, particularly when used in combination with other drugs.

## **Why the Correct Answer is Right**
The correct answer, **Dexamethasone**, when co-administered with lenalidomide, significantly increases the risk of thrombosis. This is because dexamethasone, a corticosteroid, can induce a hypercoagulable state, thereby increasing the risk of thromboembolic events. The combination of lenalidomide and dexamethasone is a common regimen in the treatment of multiple myeloma, and guidelines often recommend prophylactic anticoagulation to mitigate this risk.

## **Why Each Wrong Option is Incorrect**
- **Option A:** There is no well-documented interaction between lenalidomide and this option (not specified) that increases the risk of thrombosis significantly.
- **Option B:** Similarly, without the specific drug listed, it's hard to address directly, but generally, not as commonly associated with increased thrombosis risk when combined with lenalidomide compared to dexamethasone.
- **Option C:** Again, without specifics, it's challenging to provide a direct explanation, but these are not typically highlighted as increasing thrombosis risk with lenalidomide to the extent dexamethasone does.

## **Clinical Pearl / High-Yield Fact**
A key clinical point to remember is that when lenalidomide is used in combination with dexamethasone, patients should be considered for prophylactic anticoagulation to reduce the risk of thromboembolic events. This is a critical consideration in the management of multiple myeloma and other conditions treated with this regimen.

## **Correct Answer:** D. Dexamethasone